{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:49Z","timestamp":1792715869279,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004897","name":"EORTC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108576","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:49:55Z","timestamp":1790182195000},"page":"108576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized medicine, scientific revolution or self-serving illusion: viewpoint from EORTC-PAMM Group"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-925X","authenticated-orcid":false,"given":"V.","family":"Debien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Geraud-Cremieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-1289","authenticated-orcid":false,"given":"M.","family":"Le Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-6896","authenticated-orcid":false,"given":"I.","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-2877","authenticated-orcid":false,"given":"G.J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7565-7504","authenticated-orcid":false,"given":"E.","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-9813","authenticated-orcid":false,"given":"M.","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108576_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/d41573-025-00001-5","article-title":"2024 FDA approvals","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108576_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nrd.2016.184","article-title":"Phase II and phase III failures: 2013-2015","volume":"15","author":"Harrison","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-017133","article-title":"The financial toxicity of cancer: unveiling global burden and risk factors\u2013a systematic review and meta-analysis","volume":"10","author":"Kitaw","year":"2025","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.esmoop.2026.108576_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115593","article-title":"Dose optimization in cancer drug development: review and outcome of a multi-stakeholder workshop","volume":"226","author":"Glasmacher","year":"2025","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/psp4.13079","article-title":"Realizing the promise of Project Optimus: challenges and emerging opportunities for dose optimization in oncology drug development","volume":"13","author":"Gao","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108576_bib8","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.2003.12.044","article-title":"Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?","volume":"21","author":"Yee","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103965","article-title":"Safety of solid oncology drugs in older patients: a narrative review","volume":"9","author":"Rousseau","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108576_bib10","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108576_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000445","article-title":"Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma","volume":"3","author":"Doherty","year":"2018","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.757","article-title":"Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology","volume":"9","author":"Chatelut","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108576_bib13","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","article-title":"Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma","volume":"19","author":"Feng","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib14","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/cancers11111784","article-title":"Is there an exposure-response relationship for nivolumab in real-world NSCLC patients?","volume":"11","author":"Bellesoeur","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.108576_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.12.008","article-title":"Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer","volume":"109","author":"Basak","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt.656","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108576_bib17","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12132","article-title":"Using model-based \u201clearn and confirm\u201d to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial","volume":"6","author":"Elassaiss-Schaap","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108576_bib19","doi-asserted-by":"crossref","first-page":"S866","DOI":"10.1016\/j.annonc.2024.08.1435","article-title":"1380P PK\/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: the PIONeeR trial","volume":"35","author":"Ciccolini","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108576_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lungcan.2023.02.009","article-title":"Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: a prospective exploratory clinical trial","volume":"178","author":"Wang","year":"2023","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib21","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/psp4.13063","article-title":"Killing a fly with a sledgehammer: atezolizumab exposure in real-world lung cancer patients","volume":"12","author":"Marolleau","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.esmoop.2026.108576_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102922","article-title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","volume":"135","author":"G\u00e9raud","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108576_bib23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.annonc.2026.04.008","article-title":"Re-evaluating antibody\u2013drug conjugate linker stability: assessment, interpretation, and clinical translation","volume":"37","author":"Colombo","year":"2026","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/cpt.3495","article-title":"Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic triple-negative breast cancer","volume":"117","author":"Sathe","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcph.2295","article-title":"Trastuzumab deruxtecan dosing in human epidermal growth factor receptor 2-positive gastric cancer: population pharmacokinetic modeling and exposure-response analysis","volume":"63","author":"Yoshihara","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108576_bib26","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.ejca.2014.07.013","article-title":"On the use of pharmacogenetics in cancer treatment and clinical trials","volume":"50","author":"Robert","year":"2014","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.108576_bib28","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmoop.2026.108576_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-pharmtox-030920-025745","article-title":"Challenges and opportunities in implementing pharmacogenetic testing in clinical settings","volume":"61","author":"Chang","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.esmoop.2026.108576_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103342","article-title":"Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments","volume":"166","author":"Gougis","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108576_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108576_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hon.2335","article-title":"Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450, transporters, and acid suppression therapy","volume":"35","author":"Gay","year":"2017","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108576_bib34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/j.1875-9114.2012.01117","article-title":"Effects of tobacco smoking and nicotine on cancer treatment","volume":"32","author":"Petros","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"7968","key":"10.1016\/j.esmoop.2026.108576_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.108576_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"O\u2019Reilly","year":"2026","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108576_bib39","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108576_bib40","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","article-title":"Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small molecule reactivator","volume":"15","author":"Puzio-Kuter","year":"2025","journal-title":"Cancer Discov"},{"issue":"2 suppl 1","key":"10.1016\/j.esmoop.2026.108576_bib41","article-title":"Rezatapopt, a selective p53 reactivator, in advanced or metastatic solid tumours with a TP53 Y220C mutation: interim efficacy results from patients with ovarian cancer in the phase 2 PYNNACLE trial","volume":"36","author":"Frenel","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108576_bib43","article-title":"INVOKE: a phase 1 study of OKN4395, a first-in-class EP2\/EP4\/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors","volume":"43","author":"Chawla","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108576_bib44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-021-00231-x","article-title":"Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC","volume":"5","author":"Peters","year":"2021","journal-title":"NPJ Precis Onc"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108576_bib46","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108576_bib47","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108576_bib48","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib49","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib51","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","article-title":"Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer","volume":"99","author":"McCowan","year":"2008","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108576_bib52","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.19.01758","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108576_bib53","doi-asserted-by":"crossref","first-page":"1837812","DOI":"10.3389\/fimmu.2026.1837812","article-title":"Impact of time-of-day on immune checkpoint inhibitor therapy in cancer patients: an up-to-date clinical review","volume":"17","author":"Bacalam","year":"2026","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108576_bib54","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/0959-8049(95)00242-B","article-title":"Chronomodulation of chemotherapy against metastatic colorectal cancer","volume":"31","author":"L\u00e9vi","year":"1995","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib55","first-page":"1676","article-title":"Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients","volume":"48","author":"Petit","year":"1988","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1081\/CBI-120002597","article-title":"Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics","volume":"19","author":"Milano","year":"2002","journal-title":"Chronobiol Int"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib57","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s12672-025-03883-4","article-title":"The role of circadian genes in predicting immunotherapy response and survival outcomes in cancer patients","volume":"16","author":"Wu","year":"2025","journal-title":"Discov Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.108576_bib58","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.18632\/aging.204386","article-title":"Circadian rhythm-related factors of PER and CRY family genes function as novel therapeutic targets and prognostic biomarkers in lung adenocarcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib59","first-page":"261","article-title":"Evolution of chemotherapy","volume":"41","author":"Kennedy","year":"1991","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108576_bib60","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108576_bib61","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.esmoop.2026.108576_bib62","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108576_bib63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1479-5876-11-307","article-title":"Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients","volume":"11","author":"Petricevic","year":"2013","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108576_bib65","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108576_bib67","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","volume":"26","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib68","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat Commun"},{"issue":"7997","key":"10.1016\/j.esmoop.2026.108576_bib69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/d41586-024-00216-3","article-title":"Forget lung, breast or prostate cancer: why tumour naming needs to change","volume":"626","author":"Andr\u00e9","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108576_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104031","article-title":"Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned","volume":"29","author":"Hogervorst","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.esmoop.2026.108576_bib71","series-title":"Access to personalised oncology in Europe","author":"Gill","year":"2020"},{"key":"10.1016\/j.esmoop.2026.108576_bib72","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bcp.12258","article-title":"Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response","volume":"79","author":"Bender","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108576_bib74","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cancers15123233","article-title":"Dose optimization in oncology drug development: the emerging role of pharmacogenomics, pharmacokinetics, and pharmacodynamics","volume":"15","author":"Papachristos","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/bjc.1990.35","article-title":"Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations","volume":"61","author":"Newell","year":"1990","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib76","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/cas.15736","article-title":"Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight","volume":"114","author":"Fujiwara","year":"2023","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib77","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/bcp.15123","article-title":"Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide\/dexamethasone","volume":"88","author":"Thai","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108576_bib78","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/psp4.13016","article-title":"Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma","volume":"12","author":"Collins","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib79","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/cpt.2752","article-title":"Integration of pharmacokinetics, pharmacodynamics, safety, and efficacy into model-informed dose selection in oncology first-in-human study: a case of roblitinib (FGF401)","volume":"112","author":"Wilbaux","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2026.108576_bib80","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib81","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/jcph.2074","article-title":"Extension of the alternative intravenous dosing regimens of atezolizumab into combination settings through modeling and simulation","volume":"62","author":"Liu","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108576_bib82","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12642","article-title":"Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology","volume":"10","author":"Sanghavi","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib83","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/psp4.13070","article-title":"Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma","volume":"13","author":"Du","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108576_bib84","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt.3510","article-title":"Barriers and facilitators for bringing model-informed precision dosing to the patient\u2019s bedside: a systematic review","volume":"117","author":"Dibbets","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States","volume":"27","author":"Mudumba","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2026.108576_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1412292","article-title":"Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial","volume":"15","author":"You","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00280-025-04764-x","article-title":"Model-informed development of a cost-saving dosing regimen for enfortumab vedotin","volume":"95","author":"Op \u2019t Hoog","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108576_bib88","article-title":"Incidence and risk of peripheral sensory neuropathy with enfortumab vedotin in patients with advanced urothelial cancer: a systematic review and meta-analysis","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108576_bib89","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108576_bib90","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to anti-NECTIN4 antibody-drug conjugate enfortumab vedotin in urothelial cancer","volume":"10","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.esmoop.2026.108576_bib91","article-title":"Impact of Food and Drug Administration Project Optimus guidance on design of early-phase clinical trials","volume":"2","author":"Bhamidipati","year":"2025","journal-title":"JCO Oncol Adv"},{"issue":"35","key":"10.1016\/j.esmoop.2026.108576_bib92","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO-24-01372","article-title":"Combining response and toxicity data to implement Project Optimus","volume":"42","author":"Maki","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108576_bib93","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-15-2644","article-title":"Rendering the 3 + 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy","volume":"22","author":"Nie","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib94","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/1078-0432.CCR-09-1993","article-title":"An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics","volume":"16","author":"LoRusso","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108576_bib95","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S1470-2045(24)00134-7","article-title":"Dose selection of novel anticancer drugs: exposing the gap between selected and required doses","volume":"25","author":"Op \u2018t Hoog","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108576_bib96","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40271-025-00788-w","article-title":"Patient-reported outcomes in early-phase oncology clinical trials: a stepping stone to a patient-centered drug development","volume":"19","author":"Fiteni","year":"2026","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cts.12641","article-title":"Dose finding in the clinical development of 60 US Food and Drug Administration-approved drugs compared with learning vs. confirming recommendations","volume":"12","author":"Lyauk","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108576_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225938","article-title":"Comprehensive value assessment of drugs using a multi-criteria decision analysis: an example of targeted therapies for metastatic colorectal cancer treatment","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108576_bib99","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/psp4.12394","article-title":"Exposure-response-based product profile\u2013driven clinical utility index for ipatasertib dose selection in prostate cancer","volume":"8","author":"Zhu","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108576_bib100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cpt.3298","article-title":"Dose optimization in oncology drug development: an International Consortium for Innovation and Quality in Pharmaceutical Development White Paper","volume":"116","author":"Samineni","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib101","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40262-024-01382-3","article-title":"Pharmacogenetic testing or therapeutic drug monitoring: a quantitative framework","volume":"63","author":"Centanni","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2026.108576_bib102","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO-25-01453","article-title":"Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 precision oncology study: molecular profiling to match individually dosed, personalized drug combinations","volume":"44","author":"Sicklick","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.esmoop.2026.108576_bib103","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2022.40.16_suppl.1574","article-title":"PRECISE CURATE.AI: a prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence","volume":"40","author":"Blasiak","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108576_bib104","series-title":"Use of real-world evidence in regulatory decision making\u2013EMA publishes review of its studies","year":"2023"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib105","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/EDE.0000000000001633","article-title":"An overview of current methods for real-world applications to generalize or transport clinical trial findings to target populations of interest","volume":"34","author":"Ling","year":"2023","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/psp4.12894","article-title":"An introduction to causal inference for pharmacometricians","volume":"12","author":"Rogers","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108576_bib107","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2026.108576_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192388","article-title":"2023 GEIS Guidelines for gastrointestinal stromal tumors","volume":"15","author":"Serrano","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.13049","article-title":"Body mass index affects imatinib exposure: real-world evidence from TDM with adaptive dosing","volume":"39","author":"Maroselli","year":"2025","journal-title":"Fundam Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108576_bib110","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/annonc\/mdv030","article-title":"Alternate sunitinib schedules in patients with metastatic renal cell carcinoma","volume":"26","author":"Kalra","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02967619","article-title":"Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity","volume":"10","author":"Kuroi","year":"2003","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103477","article-title":"Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes","volume":"9","author":"Giraud","year":"2024","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108576_bib113","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.18.00725","article-title":"Phase I dose-escalation study of once weekly or once every two weeks administration of high-dose sunitinib in patients with refractory solid tumors","volume":"37","author":"Rovithi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108576_bib114","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/ph14060494","article-title":"Clinical-based vs. model-based adaptive dosing strategy: retrospective comparison in real-world mRCC patients treated with sunitinib","volume":"14","author":"Ferrer","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"17","key":"10.1016\/j.esmoop.2026.108576_bib115","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMp1310102","article-title":"The randomized registry trial\u2013the next disruptive technology in clinical research?","volume":"369","author":"Lauer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108576_bib116","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: National Cancer Registration Dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.esmoop.2026.108576_bib117","doi-asserted-by":"crossref","first-page":"140","DOI":"10.18632\/oncotarget.28703","article-title":"Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: bringing next-generation precision oncology to patients","volume":"16","author":"El-Deiry","year":"2025","journal-title":"Oncotarget"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:43Z","timestamp":1792712503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926025214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":115,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926025214"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108576","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized medicine, scientific revolution or self-serving illusion: viewpoint from EORTC-PAMM Group","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108576"}}